Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anaprazole + amoxicillin + clarithromycin + bismuth is a four-drug oral combination designed for the eradication of *Helicobacter pylori* infection, particularly in patients with peptic ulcers or gastritis. Anaprazole is a proton pump inhibitor (PPI) that reduces gastric acid secretion, creating a favorable environment for antibiotic action. Amoxicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis, while clarithromycin is a macrolide antibiotic that inhibits protein synthesis by binding to 50S ribosomal subunits. Bismuth salts possess antimicrobial effects against *H. pylori* and have mucosal protective properties. Together, this combination targets the eradication of *H. pylori* through multiple, complementary mechanisms and is typically used where resistance to clarithromycin or metronidazole is a concern[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anaprazole + amoxicillin + clarithromycin + bismuth.